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Several important contributions to the ﬁ eld of neuro-
critical care were published in Critical Care during 2010. 
Th ese articles can be gathered into six key areas: diag-
nostic criteria, delirium and encephalopathy, predict ing 
neurologic outcome after cardiac arrest, subarachnoid 
hemorrhage (SAH) and outcome from neurocritical care.
Diagnostic criteria
Meningitis
Favorable outcome from bacterial meningitis requires 
rapid diagnosis and immediate initiation of antibiotic 
therapy [1], yet distinguishing between bacterial and 
non bacterial meningitis can sometimes prove diﬃ  cult. 
Th e use of cerebrospinal ﬂ uid (CSF) lactate, as opposed 
to conventional tests (such as CSF glucose, CSF/plasma 
glucose ratio, CSF protein concentration, and CSF 
leukocyte count), has been investigated in a number of 
studies to distinguish between bacterial and nonbacterial 
meningitis.
Huy and coworkers performed a literature review and 
meta-analysis to evaluate the usefulness of CSF lactate 
concentration for this purpose [2]. From the 25 studies 
they identiﬁ ed, the authors concluded that CSF lactate 
alone had a high degree of accuracy in distinguishing 
between bacterial and nonbacterial meningitis and 
performs better than the conventional tests routinely 
used. CSF lactate was found to be less useful if its concen-
tration was low, but when elevated it was helpful, 
especially if the diagnosis was otherwise inconclusive. 
Th is suggests that any elevation in CSF lactate 
concentration above normal for the assay used could be 
employed as a diagnostic marker despite the diﬀ erence in 
cut-oﬀ  values caused by variance in methods, instru-
ments and hospital laboratories. While the authors 
conclude CSF lactate is a useful marker to distinguish 
between bacterial and nonbacterial meningitis, it is not 
meant to replace conventional tests as they are necessary 
to diagnose meningitis. Rather, interpretation of lactate 
alone is a better discriminator between bacterial and 
nonbacterial meningitis than conventional tests. As a 
result, measurements of CSF lactate may be considered 
part of standard practice to distinguish between bacterial 
and nonbacterial meningitis.
Critical illness myopathy
Critical illness myopathy (CIM) frequently complicates 
serious illness and often results in prolonged mechanical 
ventilation. Th is complication is characterized by the 
atrophy of type II muscle ﬁ bers and thick ﬁ laments, as 
well as nonexcitable muscle membranes [3]. Risk factors 
for developing CIM are not well understood.
Weber-Carstens and colleagues performed a pros pec-
tive observational study of 40 ICU patients with a 
Simpliﬁ ed Acute Physiology Score II ≥20 to identify risk 
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factors for CIM. Patients were evaluated on three con-
secutive days within 1 week of ICU admission [4]. Th e 
authors investigated demographics, inﬂ ammatory, meta-
bolic and hemodynamic parameters, and medical treat-
ment prior to the ﬁ rst nonelectromyography signs of 
CIM. On univariate analysis, inﬂ ammation, disease 
severity, decreased insulin sensitivity, catecholamine use 
and sedation requirements were all signiﬁ cantly asso-
ciated with CIM. Low-dose hydrocortisone treatment in 
septic shock and adminis tration of neuromuscular 
blocking agents or aminoglyco sides, however, were not 
related to CIM. In a multivariate Cox proportional 
hazard regression analysis, IL-6 was the only independent 
risk factor for CIM (95% conﬁ dence interval (CI) = 1.00 
to 1.01; P = 0.005); however, the overall eﬀ ect was small. 
Th e authors hypothesize that impairment of growth-
factor-mediated intracellular signal ing induced by 
systemic inﬂ ammation is important in the patho physio-
logy of CIM. A weakness of this study was that subject 
blood samples were only taken at two separate time 
points, which makes it impossible to determine the daily 
course of the inﬂ ammatory parameters.
Delirium/encephalopathy
In hospitalized patients, delirium is associated with 
increased mortality, length of stay and cost [5,6]. Th e 
epidemiology of delirium in ICUs is poorly understood, 
however, in part because its evaluation has been limited 
to single-center studies. Salluh and coworkers performed 
a 1-day point-prevalence study in 104 ICUs [7]. Patients 
were excluded if they had Glasgow Coma Scale (GCS) 
<14 from a primary neurologic diagnosis, were legally 
blind or deaf, could not speak the language of the country 
where the ICU was located, or were moribund. Of the 
975 patients screened, only 497 were enrolled. Because of 
the use of sedative drugs, only 232 (46.6%) of the enrolled 
patients could be evaluated. Of the patients evaluated, 75 
met the diagnostic criteria for delirium using the Confu-
sion Assessment Method for the ICU. Th e authors found 
delirium to be associated with higher mortality, and 
longer ICU and hospital length of stays. Th is suggests 
that sicker patients have a higher risk of developing 
delirium, as well as a higher risk of staying longer or 
dying in the ICU. Th e main modiﬁ able risk factors were 
the use of invasive devices and sedatives (midazolam). 
Th is study conﬁ rmed ﬁ ndings from single-center studies 
indicating that delirium is common in ICU patients and 
is associated with longer length of stay and adverse 
outcomes. Important weaknesses of this study are the 
high number of patients excluded and that so many 
patients could not be assessed due to sedation. Hence, 
only 24% of those patients originally screened were 
evaluated for delirium. Th is raises an important question 
of whether we are sedating too many patients in the ICU. 
In addition, the true incidence of delirium in the ICU is 
diﬃ  cult to determine from this study due to the exclusion 
of the majority of patients.
Another important insight into delirium was reported 
by Mu and colleagues in a prospective cohort study [8]. 
In postoperative patients who had undergone coronary 
artery bypass graft surgery they measured serum cortisol 
levels and assessed their relationship to delirium. A total 
of 243 patients were assessed for delirium twice daily 
during the ﬁ rst ﬁ ve postoperative days using the 
Confusion Assess ment Method for the ICU. Th e presence 
of delirium was compared with serum cortisol measured 
on the morning of the ﬁ rst postoperative day. 
Postoperative delirium was identiﬁ ed in 50% of patients 
(n = 123). A high serum cortisol level (odds ratio (OR) = 
3.09, 95% CI = 1.76 to 5.41, P  <0.001), occurrence of 
complications during the ﬁ rst day after surgery (OR = 
2.49, 95% CI = 1.18 to 5.21, P  =  0.016), a history of 
diabetes mellitus (OR = 1.91, 95% CI = 1.00 to 3.62, P = 
0.049), prolonged duration of surgery (OR = 1.36, 95% CI 
= 1.01 to 1.83, P = 0.043) and increasing age (OR = 1.11, 
95% CI = 1.06 to 1.16, P <0.001) were all associated with 
increased risk of postoperative delirium. Postoperative 
delirium was also associated with increased length of stay 
and with worse outcome.
Th is study has some limitations. Serum cortisol levels 
were not measured at baseline and were measured only 
once after surgery. As a result the data could potentially 
be skewed prior to surgery by including patients who had 
elevated cortisol and who might have been at greater risk 
of developing postoperative delirium due to preexisting 
conditions. In addition, the investigators did not perform 
baseline psychiatric or cognitive screening tests. Any 
mental disorders present prior to surgery could inﬂ uence 
the development of postoperative delirium.
Systemic infections can cause serious cognitive dys-
function in ICU patients, which may be related to 
proinﬂ ammatory cytokines. IL-1 is a likely cytokine 
candi date due to its inﬂ uence on both the immune 
system as well as the central nervous system. To address 
this question, Terrando and colleagues investigated the 
development of LPS-induced cognitive dysfunction in 
wild-type and IL-1 knockout mice [9]. After lipo poly-
saccharide (LPS) challenge, performance on behavioral 
tests of memory and response to novel environments 
deteriorated and reactive microgliosis was seen in the 
hippocampus. In addition, plasma TNFα, IL-1β, IL-6, 
and high-mobility group box-1, IL-6 and IL-1β mRNA all 
increased. Administration of IL-1 receptor antagonist 
signi ﬁ cantly reduced plasma cytokines and hippocampal 
micro gliosis, and ameliorated cognitive dysfunction; 
similar results were seen in IL-1 knockout mice without 
receiving IL-1 receptor antagonist. Th ese data suggest 
that behavioral dysfunction could be prevented by 
Scalfani and Diringer Critical Care 2011, 15:237 
http://ccforum.com/content/15/6/237
Page 2 of 6
blocking the IL-1 signal, attenuating the inﬂ ammatory 
cascade. Future studies would need to be carried out to 
determine whether responses are seen in patients.
Sepsis-associated encephalopathy (SAE) is deﬁ ned as 
diﬀ use cerebral dysfunction that is caused by a systemic 
response to infection without any evidence of a central 
nervous system infection [10,11]. However, the patho-
physiology of SAE is not well understood. In a pros-
pective cohort study, Berg and colleagues found that 
brain function might be impaired during systemic in-
ﬂ am mation due to a reduction in the plasma ratio 
between branched-chain amino acids and aromatic 
amino acids (BCAA/AAA ratio), which alters their 
uptake into the brain [12]. Twelve healthy adult male 
subjects (aged 20 to 33) were enrolled. After an overnight 
fast, all subjects underwent measurements of cerebral 
blood ﬂ ow (CBF), plasma BCAA/AAA ratio, cerebral 
delivery, net exchange of large amino acids and ammonia 
level. Paired arteriojugular venous blood samples were 
taken at baseline and after a 4-hour continuous 
intravenous infu sion of puriﬁ ed Escherichia coli LPS. 
Th is LPS infusion resulted in an increase in plasma 
phenylalanine and a signiﬁ cant decrease in the 
concentration of all other large neutral amino acids 
except for isoleucine. As the BCAA/AAA ratio decreased, 
there was an increase in the levels of the neurotoxic AAA 
phenylalanine – suggesting a relationship to encephalo-
pathy. In this study, however, the investigators did not 
perform cognitive tests on the subjects. Th ere fore, while 
systemic inﬂ ammation may aﬀ ect brain function by 
reducing the BCAA/AAA ratio, it is diﬃ  cult to draw any 
conclusions regarding the role of the BCAA/AAA ratio in 
SAE until cognitive function is assessed.
In another study investigating the pathophysiology of 
SAE, Szatmári and colleagues assessed cerebrovascular 
reactivity using an acetazolamide challenge in SAE 
patients [13]. In a prospective cohort, patients with 
clinical sepsis and disturbances of consciousness of any 
degree were studied. In addition, 20 age-matched and 
sex-matched controls without previous diseases aﬀ ecting 
cerebral vasoreactivity were also included. Transcranial 
Doppler blood ﬂ ow velocities were then measured at 
baseline and 5, 10, 15 and 20 minutes after intravenous 
administration of 15 mg/kg acetazolamide. Th e time 
course of the CBF velocity response to acetazolamide was 
measured and cerebrovascular reactivity was calculated 
(the percentage increase in the mean blood ﬂ ow velocity). 
In addition, the maximum vasodilatory eﬀ ect (cerebro-
vascular reserve capacity) was determined. Th e authors 
found that the time course of the vasomotor reaction to 
acetazolamide was delayed and the maximal vasodilatory 
response was reduced in SAE patients. Th e authors 
propose that cerebral hemodynamic changes might be 
involved in early pathogenesis of SAE.
SAE is common in patients with septic shock and has 
been associated with elevated levels of brain-speciﬁ c 
S100β protein. In some studies, treatment of septic 
patients with drotrecogin alfa (DrotAA) reduces mor-
tality in patients with severe sepsis-induced organ failure. 
Spapen and coworkers sought to determine whether 
DrotAA would reduce S100β levels and sepsis-associated 
encephalopathy [14]. Patients with pre-existing or acute 
neurological disorders were excluded. Th ose enrolled 
were classiﬁ ed into two groups based on their level of 
consciousness: GCS ≥13 and GCS <13. DrotAA was 
given as a continuous infusion of 24 μg/kg/hour for 
96  hours. Th e level of S100β was measured before 
sedation and serially after the start of DrotAA infusion. 
Of the 54 patients in the study, one-half had elevated 
S100β levels. In patients with GCS <13 receiving DrotAA, 
S100β levels fell from baseline at 64 and 96 hours (both 
P  <0.05). In addition, those who received DrotAA had 
signiﬁ cantly lower S100β levels at 64 and 96  hours 
compared with those who did not receive treatment. In 
patients with GCS ≥13, however, DrotAA had no eﬀ ect 
on S100β levels. Th ese data suggest an association 
between the severity of SAE and serum levels of S100β, 
but the measure of encephalopathy was limited.
Cardiac arrest
Our ability to predict neurological outcome of patients 
who remain comatose following cardiac arrest is limited. 
In addition, the existing data must be re-evaluated due to 
advent of treatment with hypothermia. Choi and colleagues 
sought to determine whether diﬀ usion-weighted magnetic 
resonance imaging (MRI) could improve prediction of 
outcome [15]. Th ey studied 39 patients who suﬀ ered out-
of-hospital cardiac arrest, performing diﬀ usion-weighted 
MRI within 5 days of cardiac arrest and then comparing 
functional outcome at 3  months. Patients were treated 
with hypothermia in the latter half of the study, limiting 
interpretation. Diﬀ usion-weighted MRI ﬁ ndings were 
categorized into four patterns: normal, isolated cortical 
injury, isolated deep gray nuclei injury, and mixed injury 
(cortex and deep gray nuclei). Twenty-three subjects with 
normal MRI scans served as controls. Th e authors found 
that a mixed pattern of brain injury involving cortex and 
deep gray nuclei on MRI predicted an unfavorable 
outcome, deﬁ ned as a Glasgow Outcome Scale (GOS) 
score of 1 to 3.
Another approach to predicting neurological outcome 
of cardiac arrest patients involved the use of serum 
biomarkers. Steﬀ en and colleagues investigated the 
ability of neuron-speciﬁ c enolase to predict outcome 
from cardiac arrest treated with hypothermia [16]. 
Ninety-seven subjects were compared with 133 historical 
cardiac arrest patients not treated with hypothermia. In 
this observational prospective cohort study, serum 
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neuron-speciﬁ c enolase was measured 72  hours after 
ICU admission and the neurological outcome (Pittsburgh 
cerebral performance category) was recorded at ICU 
discharge. In univariate analysis, neuron-speciﬁ c enolase 
serum levels were lower in patients treated with hypo-
thermia. Th e 72-hour neuron-speciﬁ c enolase cut-oﬀ 
levels, however, did not reliably predict poor neurological 
outcome. Th e authors also note that 1-year survival was 
signiﬁ cantly higher for the hypothermia group compared 
with the historical nonhypothermic controls.
Rossetti and coworkers focused on the use of con-
tinuous electroencephalogram (EEG) to predict outcome 
in cardiac arrest patients treated with hypothermia [17]. 
In a cohort of 34 patients, continuous EEG demon-
strating nonreactive or discontinuous background during 
hypothermia was strongly associated with unfavorable 
outcome in their patients. In addition, nonreactive 
background EEG was 100% predictive of mortality (95% 
CI = 74 to 100%) with a false-positive rate of 0 (95% CI = 
0 to 18%). Th ese data suggest that early continuous EEG 
ﬁ nd ings might be a better predictor of outcome than 
biomarkers or imaging.
Spontaneous aneurysmal subarachnoid 
hemorrhage
Th e most common and potentially treatable cause of 
secondary neurological injury after aneurysmal SAH is 
delayed cerebral ischemia (DCI). DCI occurs several days 
after hemorrhage and is considered to result from 
reductions in CBF below critical ischemic thresholds. 
Several factors are thought to contribute to DCI 
including large artery vasospasm, impaired cerebral 
autoregulation and intravascular volume depletion [18]. 
Triple-H therapy (hypervolemia, hypertension, hemo-
dilu tion) is the mainstay treatment of DCI with the goal 
of increasing cerebral perfusion pressure. Dankbaar and 
colleagues performed a systematic review of the literature 
address ing the eﬀ ectiveness of triple-H therapy and its 
com ponents on clinical outcome [19]. Eleven studies of 
triple-H therapy were identiﬁ ed and included in their 
meta-analysis. Th e authors concluded that hemodilution 
did not change CBF and that only one of the seven 
studies on hypervolemia showed a signiﬁ cant increase in 
CBF. Th ere was a signiﬁ cant increase in CBF in two of the 
four studies applying hypertension and in one study using 
triple-H therapy. None of these studies used control 
groups or randomi zation. Th e authors conclude that 
there is no evidence from controlled studies for a 
beneﬁ cial eﬀ ect of triple-H therapy or its separate 
components on CBF in SAH patients.
Th e conclusion that there is no evidence to support 
triple-H therapy is misleading, however, as the treatment 
has not been properly studied to date. Th is systematic 
review points out the lack of well-designed studies. 
Owing to the amount of underpowered and poorly 
designed studies, it is diﬃ  cult to come to any conclusions 
regarding eﬀ ectiveness.
In a prospective cohort study, Bendel and coworkers 
evaluated neuroendocrine status after SAH and its impact 
on clinical outcome [20]. Th ey enrolled 30 subjects and 16 
controls. Th e study focused on insulin-like growth factor-1 
(IGF-1), which is associated with neuronal growth, cell 
death and apoptosis after ischemic stroke [21]. Th e 
authors found that serum IGF-1 concen trations were 
signi ﬁ  cantly lower in SAH patients on days 1 to 5 com-
pared with controls (P = 0.01). Th ere was no signiﬁ cant 
diﬀ erence at 3 months between the groups. In addition, 
there was no relationship between the severity of SAH 
and the IGF-1 concentration. Th e data showed patients 
with GOS ≤4 had lower IGF-1 concen trations and lower 
health-related quality of life compared with patients with 
higher GOS scores. Th is is the ﬁ rst pub lished study to 
evaluate IGF-1 in the acute phase of aneurysmal SAH. 
Th e authors suggest that low IGF-1 following SAH might 
be associated with poor outcome or death.
Pulmonary edema is common after SAH [22], but its 
management is complicated by the need to rigorously 
avoid hypovolemia in these patients. Hoﬀ  and colleagues 
prospectively studied intravascular volume (using pulse 
dye densitometry) in 102 SAH patients, comparing those 
with and without pulmonary edema [23]. Surprisingly, 
those patients who developed pulmonary edema (17 out 
of 102) had lower mean circulating blood volume than 
those without. As a result, ﬂ uid management in SAH 
patients that develop pulmonary edema is more diﬃ  cult. 
Th e authors concluded that treatment for pulmonary 
edema with diuresis must be weighed against the risk of 
worsening hypovolemia in SAH patients and thus 
increasing the risk of DCI.
Outcome from neurocritical care
Despite advances in diagnosis and treatment, patients 
admitted to a neurocritical care unit have poor functional 
outcome and high mortality [24]. In a retrospective 
review of 796 consecutive patients admitted to a non-
surgical neurocritical care unit, Kiphuth and colleagues 
found an in-hospital mortality of 22.5%. Good long-term 
functional outcome (determined by the modiﬁ ed Rankin 
Scale) was seen in only 28.4% [25]. Variables found to be 
independently associated with outcome were admission 
diagnosis, age, duration of mechanical ventilation and 
Th erapeutic Intervention Scoring System-28 on day 1. 
When diagnoses were compared, the authors found that 
patients with Guillain–Barré syndrome and myasthenia 
gravis had a good long-term outcome more often than 
those with other diagnoses.
In another study, Kiphuth and colleagues investigated 
the relationship between functional outcome and 
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retro spective agreement to neurocritical care [26]. Th e 
purpose of this study was to determine whether retro-
spective consent to neurocritical care was inﬂ uenced by 
func tional outcome. In this study of 704 consecutive 
patients admitted to a nonsurgical neurocritical care 
unit, 91% of patients who were independent at 1 year 
would again agree to the care they received. Only 19% of 
those who were dependent for activities of daily living, 
however, would have agreed retrospectively to 
neurocritical care. Th e authors conclude that eﬀ orts must 
be taken to increase public awareness regarding the 
importance of advanced directives, and further research 
must focus on determining highly speciﬁ c and sensitive 
predictors for outcome in these patients.
In patients suﬀ ering from nontraumatic supratentorial 
intracerebral hemorrhage, the inﬂ uence of anemia on 
functional outcome and mortality was investigated by 
Diedler and colleagues. In a retrospective cohort study of 
196 patients, 23.5% had a favorable outcome (moderate 
disability or better) [27]. Th e mean hemoglobin concen-
tration was signiﬁ cantly lower (12.3 versus 13.7  g/dl, 
P  <0.001) in those with poor outcome. On multivariate 
analysis, the independent predictors of poor outcome at 
90 days were mean hemoglobin, age and NIH Stroke 
Scale score on admission. Th e authors conclude, however, 
that they could not determine whether anemia causes 
further brain injury or is a marker of severe injury. 
Despite the diﬀ erence in mean hemoglobin in those 
patients with poor outcome, this is of uncertain clinical 
signiﬁ cance.
Outcome after traumatic brain injury is diﬃ  cult to 
predict. Recent investigations have looked into a variety 
of biomarkers to better predict and monitor outcome 
after brain trauma. Biomarkers investigated include glial 
ﬁ brillary acidic protein [28], neuroﬁ lament light chain 
[29], S100 [30], tissue transglutaminases [31], ubiquitin 
[32], β-amyloid precursor proteins [33] and tau [34]. 
Dong and colleagues investigated the use of the bio-
marker resistin predicting outcome after traumatic brain 
injury. Th is group previously reported that elevated levels 
of resistin are found in blood of patients with 
intracerebral hemorrhage and that higher levels were 
asso ciated with poor outcome. Th e authors subsequently 
studied a cohort of 94 patients with severe traumatic 
brain injury and compared their resistin levels with those 
of 50 healthy controls [35]. Plasma resistin levels were 
elevated during the initial 6 hours after injury and peaked 
within 24  hours; the patients’ levels were substantially 
higher than those of the healthy controls. Plasma resistin 
levels were negatively correlated with GCS (P  <0.001) 
and were an independent predictor of 1-month survival. 
Th e data suggest that the plasma resistin level might 
reﬂ ect the initial brain injury and could become a useful 
biomarker to predict survival in these patients.
Conclusion
In 2010 the ﬁ eld of neurocritical care received increased 
attention, with an increasing number of articles being 
published in Critical Care. Th e issues of diagnostic 
criteria for meningitis and critical illness myopathy were 
further investigated. In addition, studies of the epi-
demiology, risk factors, and treatment for delirium and 
encephalopathy in the ICU were published. Aspects of 
cardiac arrest, aneurysmal SAH and outcomes in neuro-
critical care were re-addressed using new approaches. 
Overall, there were many quality articles published in 
Critical Care during 2010 that have added to our 
scientiﬁ c and clinical knowledge in the ﬁ eld of 
neurocritical care.
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